- PsyBio (PSYB) attends the Benzinga Cannabis Capital Conference, participating on a panel about nextgen psychedelics
- Levine will be sharing his knowledge and insights as a leading drug development company
- The event is on April 13 at Benzinga’s Cannabis Capital Conference at Fontainebleau Miami Beach, Florida
- In addition, the company is looking at applying to the TSXV
- PsyBio Therapeutics (PSYB) is trading at C$0.05 as of yesterday at close
PsyBio Therapeutics (PSYB) CEO, Evan Levine will participate on a nextgen psychedelics panel.
Levine will be sharing his knowledge and insights as a leading drug development company in the psychedelics sector.
In addition to speaking at the conference, Levine will hold one-on-one meetings on April 13 at Benzinga’s Cannabis Capital Conference at Fontainebleau Miami Beach, Florida.
The company also intends to apply to the TSXV for a non-brokered private placement, consisting of up to 20 million units at 5 cents each.
The aggregate gross proceeds will be worth up to $1 million.
PsyBio is looking to put proceeds towards cGMP manufacturing, clinical trials and general corporate and working capital purposes.
Born as an intellectual property driven biotech company, PsyBio Therapeutics develops novel psycho-targeted therapeutics to improve mental health and neurological conditions.
PsyBio Therapeutics (PSYB) is trading at C$0.05 as of yesterday at close.
